587 completed. 587 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 587 | Completed 587 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intubation Conditions During ERCP With Lidocaine Aerosol Plus Low-dose Cisatracurium or Conventional-dose Cisatracurium Cisatracurium 0.05 mg/kg IV, Cisatracurium 0.15 mg/kg IV, Lidocaine aerosol 2.4% topical - Intubation, Intratracheal | Phase 4 | Completed | Jiangang Song | 186 | 2025-01-17 | 2026-05-28 |
| A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. Probiotic plus lactulose, Rifaximin plus lactulose, L-ornithine-L-aspartate plus latulose - Overt Hepatic Encephalopathy | Phase 4 | Completed | Qurratul Ain Jamil | 252 | 2024-12-02 | 2025-06-25 |
| Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma hydrochloride hydromorphone + flurbiprofen axetil, conventional analgesia - Enhanced Recovery After Surgery, Multimodal Analgesia | Phase 4 | Completed | First Affiliated Hospital, Sun Yat-Sen University | 129 | 2024-08-01 | 2026-01-02 |
| Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis Sitagliptin (Januvia), Sitagliptin (JANUVIA®), Duloxetine (60 mg) once daily - Liver Cirrhosis With Diabetes | Phase 4 | Completed | Kafrelsheikh University | 64 | 2024-07-01 | 2026-02-27 |
| N-Acetyl Cysteine Effect on Liver Function After Mitral Valve Replacement N acetyl cysteine, normal saline - Oxidative Stress, Liver Dysfunction | Phase 4 | Completed | Kasr El Aini Hospital | 54 | 2024-06-30 | 2025-08-29 |
| Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis Warfarin 3 mg, Warfarin 2 mg - Liver Cirrhosis, Portal Vein Thrombosis | Phase 4 | Completed | Kafrelsheikh University | 21 | 2024-03-15 | 2026-05-06 |
| Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis Simvastatin 15 mg, Simvastatin 5 mg - Liver Cirrhosis, Portal Hypertension Related to Cirrhosis | Phase 4 | Completed | Kafrelsheikh University | 22 | 2024-03-15 | 2026-03-11 |
| Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients Nebivolol 5 mg, Carvedilol 12.5 mg, Nebivolol 2.5 mg - Liver Cirrhosis, Arterial Hypertension | Phase 4 | Completed | Kafrelsheikh University | 40 | 2024-03-01 | 2026-02-09 |
| Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC Elecsys® GAAD - Liver Cirrhosis, Hepatocellular Carcinoma | Phase 4 | Completed | Manchester University NHS Foundation Trust | 657 | 2024-01-08 | 2026-10-09 |
| Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People 2 doses of HAV, At least one dose of HAV - Hepatitis A, Immunodeficiency | Phase 4 | Completed | LiuZhou People's Hospital | 392 | 2023-12-19 | 2025-12-31 |
| Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone Liposomal bupivacaine, Bupivacaine Hydrochloride combined with dexamethasone - Liver Cancer | Phase 4 | Completed | Zhejiang Cancer Hospital | 96 | 2023-12-15 | 2025-06-26 |
| Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir Vemliver tablet, Baracross Tablet - Hepatitis B, Chronic | Phase 4 | Completed | Daewoong Pharmaceutical Co. LTD. | 196 | 2023-08-28 | 2025-03-18 |
| The COMBAT HBV Feasibility Trial Tenofovir Disoproxil Fumarate 300 MG, Hepatitis B monovalent vaccine, Placebo - Hepatitis B, Vertical Transmission of Infectious Disease | Phase 4 | Completed | University of North Carolina, Chapel Hill | 317 | 2023-08-17 | 2026-02-19 |
| The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE Oxycodone, Sufentanil - Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization | Phase 4 | Completed | The First Affiliated Hospital with Nanjing Medical University | 40 | 2023-08-07 | 2024-02-28 |
| Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD Berberine plus lifestyle intervention, Placebo plus lifestyle intervention - Obesity, Obesity, Abdominal | Phase 4 | Completed | China National Center for Cardiovascular Diseases | 337 | 2023-07-06 | 2025-01-29 |
| Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. - HIV Infections, Fatty Liver Disease | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 63 | 2023-05-26 | 2025-07-18 |
| Ketotifen in Non-Alcoholic Fatty Liver Disease Patients Ketotifen, Vitamin E - Hepatic Disease | Phase 4 | Completed | Tanta University | 60 | 2023-05-20 | 2026-02-06 |
| A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes. Dapagliflozin + Metformin, Empa - NAFLD (Nonalcoholic Fatty Liver Disease) | Phase 4 | Completed | Beni-Suef University | 108 | 2023-05-01 | 2026-02-03 |
| SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA 99mTc-Macro Albumin Aggregate - Carcinoma, Carcinoma, Hepatocellular | Phase 4 | Completed | Sirtex Medical | 5 | 2023-04-25 | 2025-01-29 |
| Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli), Recombinant Hepatitis E Vaccine (Escherichia Coli) - Hepatitis E | Phase 4 | Completed | Xiamen Innovax Biotech Co., Ltd | 612 | 2023-03-22 | 2024-08-21 |
Showing 20 of 587. Sign in to see all of them.
Hepatitis C (109) · Hepatitis C, Chronic (100) · Hepatitis B (98) · Hepatitis B, Chronic (85) · Non-alcoholic Fatty Liver Disease (45) · Carcinoma, Hepatocellular (36) · Fibrosis (34) · Liver Cirrhosis (33) · HIV Infections (25) · Diabetes Mellitus, Type 2 (23) · Hepatitis A (23) · Fatty Liver (21) · Hepatic Encephalopathy (16) · Hepatitis (16)
Digestive System Diseases (584) · Infections (394) · Virus Diseases (385) · Hepatitis (381) · Hepatitis, Viral, Human (379) · Blood-Borne Infections (367) · Communicable Diseases (366) · Pathological Conditions, Signs and Symptoms (285) · Pathologic Processes (275) · RNA Virus Infections (236) · Disease Attributes (204) · Chronic Disease (193) · Flaviviridae Infections (188) · Hepatitis, Chronic (184)
Ribavirin (107) · peginterferon alfa-2a (96) · Tenofovir (34) · entecavir (26) · Sofosbuvir (25) · Lamivudine (20) · Hepatitis B Vaccines (18) · peginterferon alfa-2b (18) · Hepatitis A Vaccines (17) · Engerix-B (14) · ledipasvir, sofosbuvir drug combination (14) · adefovir dipivoxil (13) · Telbivudine (12) · sofosbuvir-velpatasvir drug combination (12) · Pioglitazone (10)
GlaxoSmithKline (43) · Hoffmann-La Roche (42) · National Taiwan University Hospital (10) · Kirby Institute (8) · Ain Shams University (7) · Merck Sharp & Dohme LLC (7) · Novartis Pharmaceuticals (7) · Yonsei University (7) · Kaohsiung Medical University Chung-Ho Memorial Hospital (6) · University of Florida (6) · Xiamen Innovax Biotech Co., Ltd (6) · Bukwang Pharmaceutical (5) · Foundation for Liver Research (5) · Johns Hopkins University (5) · Kafrelsheikh University (5)
United States (122) · China (78) · South Korea (53) · Germany (39) · Taiwan (39) · Spain (31) · Canada (30) · Egypt (29) · Australia (22) · Belgium (20) · Thailand (19) · Brazil (18) · India (15) · Sweden (15) · United Kingdom (15)
Chen-Hua Liu, MD (6) · Ming-Lung Yu, MD, PhD (5) · Arnulf Ferlitsch, MD (3) · Cheng-Chao Liang, MD (3) · Ding-Shinn Chen, MD (3) · Hong You, Doctor (3) · Jee-Fu Huang, MD (3) · Jia-Horng Kao, MD, PhD (3) · Jun Yong Park, M.D (3) · Kenneth Cusi, M.D. (3)
PMID 32710245, PMID 37467180, PMID 20009522, PMID 21366801, PMID 22508412, PMID 22777097, PMID 23732904, PMID 24508042, PMID 24915612, PMID 26026936, PMID 26190091, PMID 26867206, PMID 29960156, PMID 30237305, PMID 30689258, PMID 33293204, PMID 35599306, PMID 36262060, PMID 37096802, PMID 39373164, PMID 39641307, PMID 39963952, PMID 10412031, PMID 10618544, PMID 11588440, PMID 11850253, PMID 11984144, PMID 12375147, PMID 12500513, PMID 15014185, PMID 15191208, PMID 15470215, PMID 15750456, PMID 16134766, PMID 16183464, PMID 16391218, PMID 16530509, PMID 1665400, PMID 16673294, PMID 17135584, PMID 17239478, PMID 17259872, PMID 17302380, PMID 17326150, PMID 17484872, PMID 17560678, PMID 17625124, PMID 17875007, PMID 17935165, PMID 17943989
2005 (4), 2019 (3), 2004 (2), 2008 (2), 2014 (2), 2015 (2), 2016 (2), 2009 (1), K23DK082621 (1), K23DK115827 (1), R01CA091912 (1), R01DA013806 (1), R01DA014502 (1), R01DA016764 (1), R01DA033777 (1)